364 related articles for article (PubMed ID: 8167332)
1. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
[TBL] [Abstract][Full Text] [Related]
2. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
Gouw SC; van den Berg HM; le Cessie S; van der Bom JG
J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
[TBL] [Abstract][Full Text] [Related]
5. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation.
Lusher J; Abildgaard C; Arkin S; Mannucci PM; Zimmermann R; Schwartz L; Hurst D
J Thromb Haemost; 2004 Apr; 2(4):574-83. PubMed ID: 15102011
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
[TBL] [Abstract][Full Text] [Related]
8. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
White GC; Courter S; Bray GL; Lee M; Gomperts ED
Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
[TBL] [Abstract][Full Text] [Related]
9. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
Aygören-Pürsün E; Scharrer I
Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
[TBL] [Abstract][Full Text] [Related]
10. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
Blanchette VS; Shapiro AD; Liesner RJ; Hernández Navarro F; Warrier I; Schroth PC; Spotts G; Ewenstein BM;
J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
[TBL] [Abstract][Full Text] [Related]
11. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
Klukowska A; Komrska V; Jansen M; Laguna P
Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
[TBL] [Abstract][Full Text] [Related]
13. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
Goodeve AC; Williams I; Bray GL; Peake IR
Thromb Haemost; 2000 Jun; 83(6):844-8. PubMed ID: 10896236
[TBL] [Abstract][Full Text] [Related]
14. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
Franchini M; Tagliaferri A; Mengoli C; Cruciani M
Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor development, safety, and efficacy of Advate
Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
[TBL] [Abstract][Full Text] [Related]
16. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
[TBL] [Abstract][Full Text] [Related]
17. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
[TBL] [Abstract][Full Text] [Related]
18. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
Int J Hematol; 2006 Aug; 84(2):158-65. PubMed ID: 16926139
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
